Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. New York

    A US randomised, placebo controlled, double blind trial to evaluate oestrogen and progestogen in postmenopausal women was stopped early by the Women's Health Initiative because health risks exceeded health benefits by a small margin.

    It is the first trial to examine whether continuous oestrogen plus progestogen has a favourable or unfavourable effect on coronary heart disease and overall risks and benefits in healthy women.

    JAMA has already posted the article on its website (http://www.jama.com/issues/v288/n3/abs/joc21036.html). The article will then be …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular